Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2024Multiple Sclerosis Journal

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

IRIzanne RoosSSSifat SharminCMCharles B. Malpas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Roos et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc4ab6db643587571ba2https://doi.org/10.1177/13524585241267211
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis2006 · 253 citations
  2. 2Defining reliable disability outcomes in multiple sclerosis2015 · 250 citations
  3. 3Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool2012 · 1,782 citations
  4. 4A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2003 · 1,249 citations
  5. 5Sensitivity analysis after multiple imputation under missing at random: a weighting approach2007 · 241 citations